Edesa Biotech Price To Book vs. Cash And Equivalents
| EDSA Stock | USD 2.44 0.14 6.09% |
For Edesa Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Edesa Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Edesa Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Edesa Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Edesa Biotech over time as well as its relative position and ranking within its peers.
Edesa |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Edesa Biotech Cash And Equivalents vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Edesa Biotech's current stock value. Our valuation model uses many indicators to compare Edesa Biotech value to that of its competitors to determine the firm's financial worth. Edesa Biotech is rated # 2 in price to book category among its peers. It is rated # 5 in cash and equivalents category among its peers creating about 4,917,278 of Cash And Equivalents per Price To Book. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edesa Biotech's earnings, one of the primary drivers of an investment's value.Edesa Cash And Equivalents vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Edesa Biotech |
| = | 2.61 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Edesa Biotech |
| = | 12.81 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Edesa Cash And Equivalents Comparison
Edesa Biotech is currently under evaluation in cash and equivalents category among its peers.
Edesa Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Edesa Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Edesa Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Edesa Biotech's change in net profit over the period of time. It can combine multiple indicators of Edesa Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -246.8 K | -234.5 K | |
| Operating Income | -8.3 M | -8.7 M | |
| Income Before Tax | -7.5 M | -7.9 M | |
| Total Other Income Expense Net | 976.5 K | 1 M | |
| Net Loss | -7.5 M | -7.9 M | |
| Income Tax Expense | 720.00 | 1,405 | |
| Interest Income | 260.9 K | 273.9 K | |
| Net Loss | -15.8 M | -15 M | |
| Net Loss | -7.5 M | -7.9 M | |
| Net Interest Income | 333.3 K | 350 K | |
| Change To Netincome | 2.6 M | 2.7 M | |
| Net Loss | (46.75) | (49.08) | |
| Income Quality | 0.51 | 0.69 | |
| Net Income Per E B T | 1.00 | 1.10 |
Edesa Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Edesa Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Edesa Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Edesa Biotech's important profitability drivers and their relationship over time.
Use Edesa Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edesa Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edesa Biotech will appreciate offsetting losses from the drop in the long position's value.Edesa Biotech Pair Trading
Edesa Biotech Pair Trading Analysis
The ability to find closely correlated positions to Edesa Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edesa Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edesa Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edesa Biotech to buy it.
The correlation of Edesa Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edesa Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edesa Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edesa Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Edesa Biotech position
In addition to having Edesa Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
To fully project Edesa Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Edesa Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Edesa Biotech's income statement, its balance sheet, and the statement of cash flows.